Bausch Health Cos (NYSE:BHC) Issues Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Bausch Health Cos (NYSE:BHC) issued its quarterly earnings data on Wednesday. The company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.11, Zacks reports. Bausch Health Cos had a net margin of 1.53% and a return on equity of 875.00%.

Here are the key takeaways from Bausch Health Cos’ conference call:

• Bausch Health (ex-Bausch + Lomb) reported a strong Q1 with 12 consecutive quarters of year-over-year revenue and adjusted EBITDA growth, revenue up ~14% (reported) and adjusted EBITDA up 17%, and management reaffirmed full‑year guidance.
• Growth was led by Xifaxan/Salix, but management reiterated risk around exclusivity—expecting a generic entrant by 1/1/2028 and a gross‑to‑net accrual adjustment effective 1/1/2027—creating downside risk to future cash flow and valuation.
• Solta delivered exceptional results driven by China after the December 2025 Shibo acquisition (reported Solta revenue +51%, China +193%), with integration cited as a durable competitive advantage for capital sales and consumables.
• Cash generation and deleveraging improved in Q1—net debt (ex-Bausch + Lomb) fell by ~$150 million, adjusted operating cash flow was strong, and U.S. opt‑out litigation payments concluded, supporting capital‑structure priorities.
• R&D and BD focus includes a U.S.-only, earlier‑randomized, highly powered larsucosterol Phase III program and continued screening of late‑stage/commercial assets; these could be value‑creating but remain execution‑ and trial‑outcome dependent.

Bausch Health Cos Stock Down 1.3%

Bausch Health Cos stock traded down $0.08 during midday trading on Wednesday, hitting $5.60. The stock had a trading volume of 1,599,717 shares, compared to its average volume of 1,974,730. The company has a current ratio of 1.47, a quick ratio of 1.08 and a debt-to-equity ratio of 54.68. The stock has a market cap of $2.09 billion, a P/E ratio of 13.32 and a beta of 0.40. Bausch Health Cos has a 12 month low of $4.41 and a 12 month high of $8.69. The business has a fifty day moving average price of $5.52 and a 200 day moving average price of $6.20.

Institutional Trading of Bausch Health Cos

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Tidal Investments LLC increased its holdings in Bausch Health Cos by 2.6% in the second quarter. Tidal Investments LLC now owns 50,131 shares of the company’s stock valued at $334,000 after buying an additional 1,276 shares during the last quarter. Commonwealth Equity Services LLC increased its holdings in Bausch Health Cos by 14.8% in the fourth quarter. Commonwealth Equity Services LLC now owns 14,067 shares of the company’s stock valued at $98,000 after buying an additional 1,812 shares during the last quarter. CANADA LIFE ASSURANCE Co increased its holdings in Bausch Health Cos by 2.5% in the second quarter. CANADA LIFE ASSURANCE Co now owns 104,156 shares of the company’s stock valued at $690,000 after buying an additional 2,552 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in Bausch Health Cos by 65.9% in the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock valued at $51,000 after buying an additional 3,106 shares during the last quarter. Finally, Squarepoint Ops LLC increased its holdings in Bausch Health Cos by 4.6% in the fourth quarter. Squarepoint Ops LLC now owns 78,715 shares of the company’s stock valued at $547,000 after buying an additional 3,495 shares during the last quarter. 78.65% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on BHC. Wall Street Zen lowered Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 15th. Raymond James Financial reaffirmed a “market perform” rating on shares of Bausch Health Cos in a research report on Monday, January 26th. Truist Financial lifted their target price on Bausch Health Cos from $7.00 to $8.00 and gave the stock a “hold” rating in a research report on Wednesday, January 7th. Royal Bank Of Canada dropped their target price on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a research report on Monday. Finally, Barclays dropped their target price on Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 25th. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus target price of $8.00.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.